Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

LKC Technologies, Inc. Announces the Availability of Integrated Normative Data on its RETeval® Device


GAITHERSBURG, Md., Oct. 5, 2017 /PRNewswire/ -- LKC Technologies is announcing that the revolutionary RETeval device's latest software release (2.8.0) includes age-adjusted normative data, which is available for human use. The reference intervals come from an ongoing clinical trial, the RETeval All Comers Trial (REACT), sponsored by LKC Technologies.

"This is the largest normative data study that LKC has ever conducted, and we are thankful that our customers have partnered with us to gather this critical patient data," said LKC Technologies President James Datovech. "With normative data integrated into the RETeval device, the physician now has valuable input to aid in their interpretation and assessment of test results on a patient. This makes the device even easier to integrate into the practice or clinic, and makes it efficient and intuitive to administer full function ERG tests, while requiring minimal ? if any ? changes to workflow."

To date, the REACT study has conducted tests in five locations in three states utilizing an IRB approved protocol. All subjects completed informed consent forms. Other statistics include:

"The handheld and portable nature of the device made it easy to bring to multiple office locations," said Retinal Specialist Robert Feig, MD of Brooklyn Eye Center. "We were able to test many patients at once, and gathering information was seamless for our technicians and patients. We have been able to see more patients and get better information on their retina function since acquiring the RETeval device last year. Our patient profile is improved since we are bridging the gap between structural and functional information, allowing us to see a full picture of eye health."

To learn more about the FDA cleared RETeval device or other products, visit www.lkc.com/reteval, email [email protected] or call +1 301.840.1992. For information on the clinical trial, visit clinicaltrials.gov and search for NCT03065881 or contact [email protected].

ABOUT LKC TECHNOLOGIES
When vision issues impact your everyday life, LKC Technologies is here to help. Building on over 40 years of experience in the visual electrophysiology field, the RETeval® device is transforming the industry for adults and children alike. Offering full flash ERG and VEP testing to gather objective information on retina function, the RETeval device brings comprehensive electrophysiology technology to any office or clinical setting. LKC Technologies is committed to developing innovative products that lead to the preservation and treatment of sight. LKC Technologies: Vision Definedtm. Visit www.LKC.com for more. RETeval is a registered trademark of LKC Technologies.

Contact:
Larissa Fair
LKC Technologies
[email protected] 
301.840.1992

 

SOURCE LKC Technologies


These press releases may also interest you

at 10:54
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...

at 10:49
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...

at 10:45
C?N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation (TSE 6523) Group Company and premier...

at 10:35
BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets. This...

at 10:30
Invensify, Inc., Santa Clara, California, has introduced a power efficient, temperature-controlled shipping container designed to maintain stable storage temperatures for high-value pharmaceuticals before and during transport to last-mile cold chain...

at 10:30
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. One of...



News published on and distributed by: